|
Volume 272, Number 48, Issue of November 28, 1997
pp. 30167-30177
Tumor Necrosis Factor- Increases ATP Content in Metabolically
Inhibited L929 Cells Preceding Cell Death*
(Received for publication, February 19, 1997, and in revised form, July 30, 1997)
José A.
Sánchez-Alcázar
,
Jesús
Ruíz-Cabello
§,
Inmaculada
Hernández-Muñoz
,
Pilar Sánchez
Pobre
,
Paz
de la Torre
,
Eva
Siles-Rivas
,
Inmaculada
García
,
Ofer
Kaplan
¶,
María T.
Muñoz-Yagüe
and
José A.
Solís-Herruzo

From the Centro de Investigación, Hospital
Universitario "12 de Octubre," Carretera de Andalucía 4,5, Madrid 28041, Spain, § Departamento de
Química-Física II, Facultad de Farmacia, Unidad de
Resonancia Nuclear Magnetice, Instituto Pluridisciplinar., Universidad
Complutense, Madrid 28040, Spain, and ¶ Department of Surgery A,
Tel-Aviv Medical Center, Tel-Aviv 64239, Israel
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENT
REFERENCES
ABSTRACT
The effects of tumor necrosis factor- (TNF) on
ATP levels were studied in metabolically inhibited L929 cells.
Treatment of these cells with TNF in the presence of actinomycin D or
cycloheximide induces cyclic changes in the intracellular ATP content
preceding cell death. After 3 h of incubation, the intracellular
ATP content increased by 48 ± 6% (p < 0.001),
but at 4 h, it decreased to the control level. Two hours later, it
increased again by 23 ± 5% over the control level
(p < 0.001). Coinciding with cell death, ATP content
decreased progressively until almost complete depletion. These changes
in ATP content were associated with parallel alterations in the
respiratory coupling and with increased generation of reactive oxygen
species. The mechanism by which TNF/actinomycin D or TNF/cycloheximide increased cellular ATP seemed to be dependent on the mitochondrial ATP
synthesis and related to the cytotoxic effect of TNF, since blockade of
mitochondrial electron transport prevented the increase in cellular
ATP, the formation of reactive oxygen species, and the apoptotic cell
death caused by TNF. We suggest that the TNF/actinomycin D- or
TNF/cycloheximide-induced changes in intracellular ATP levels may be
involved in the cytotoxic effect of TNF in metabolically inhibited L929
cells.
INTRODUCTION
Tumor necrosis factor-
(TNF)1 is a polypeptide,
mainly produced by activated macrophages and T or B lymphocytes, with a
wide range of biological activities (1-3). TNF was first described as
an antitumor cytotoxin that preferentially killed growing tumor cells
(4). Recently, it became clear that this cytokine may also exert
biological effects on a variety of normal cells, mostly related to
immunomodulatory or inflammatory processes (5, 6). The cytotoxic
activity of TNF against tumor cells has been studied extensively,
although its molecular mechanism of action is not well understood (7,
8). It has been suggested that it may not be unique and instead may be
dependent on the cell line and on the presence or absence of metabolic
inhibitors (9, 10). Although TNF alone exerts cytotoxic effects against
certain tumor cell lines, cycloheximide (CHX) and actinomycin D (AD)
have been shown to enhance TNF-mediated cell killing (11). In the
presence of CHX or AD, not only is less TNF required, but also cell
death occurs in a shorter period of time (12). This enhancement of the
cytolytic properties of TNF by inhibiting transcription by AD is the
basis for a commonly used in vitro biological assay of TNF
in biological fluids (13). Involvement of mitochondria in TNF-induced
cytotoxicity has been suggested because of the finding of abnormalities
in the mitochondria of TNF-treated cells (14). Furthermore, impaired
electron flow in the mitochondria has been detected in target cells
treated with TNF (15, 16), and synthesis of manganese superoxide
dismutase, a mitochondrial enzyme, is induced in some cells incubated
with TNF (17). Moreover, Schulze-Osthoff et al. (18) showed
that L929-° cells, lacking in mitochondrial DNA, are resistant to
the cytotoxic effect of TNF. The above observations led to the
hypothesis involving the formation of reactive oxygen species (ROS) in
the cytotoxic effect of TNF (16, 17). In this study, we describe the
changes induced by TNF in the energy charge of metabolically inhibited
L929 cells and their relationship to the respiratory coupling during
the time preceding cell death.
EXPERIMENTAL PROCEDURES
Materials
Recombinant human TNF was purchased from Genzyme Co. (Cambridge,
MA). RPMI 1640 medium was from Biochrom (Berlin, Germany), and
Dulbecco's modified Eagle's medium was from Bio-Whittaker (Verviers,
Belgium). Rotenone, AD, CHX, antimycin A, oligomycin, trypsin, Hepes,
Mops, EDTA, proteinase K, Triton X-100, ethidium bromide, propidium
iodide, mixothiazol, thenoyltrifluoroacetone (TTFA), SDS, and pyruvate
kinase were purchased from Sigma (Alcobendas, Spain). Potassium cyanide
(KCN) was from FEROSA (Barcelona, Spain); L-glutamine,
penicillin, streptomycin, and phosphate-buffered saline (PBS) were from
ICN Biomedicals Inc. (Costa Mesa, CA); and trichloroacetic acid was
from Panreac (Barcelona, Spain). Potassium hydroxide and Tris were from
Merck (Darmstadt, Germany). Fetal calf serum was from Sera-Lab (Sussex,
UK). Dihydrorhodamine 123 (DHR-123) was purchased from Molecular Probes
(Eugene, OR).
Methods
Cell Cultures
L929 murine fibrosarcoma cell line and HepG2
human hepatoma cell line were obtained from the American Type Culture
Collection (Rockville, MD). L929 cells were grown in RPMI 1640 medium,
and HepG2 cells were grown in Dulbecco's modified Eagle's medium
supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, penicillin (100 units/ml), and streptomycin
(0.1 mg/ml) at 37 °C and 5% CO2. For TNF cytotoxicity,
lactate, and ATP/ADP assays, cells were cultured in six-well plates
(35-mm-diameter well). At confluence (1 × 106
cells/plate), the medium was replaced with fresh RPMI 1640 medium in
the absence (control) or presence of 25 ng/ml TNF, 1 µg/ml AD, 0.1 mM CHX or the combined treatment, TNF and AD (TNF/AD) or
TNF and CHX (TNF/CHX), for the times indicated under "Results" and
figure legends. Mitochondrial inhibitors were added at the same time as
TNF/AD or TNF/CHX. For measurement of whole cell respiration, L929
cells were cultured in 175-cm2 flasks. At confluence
(40 × 106 cells/flask), cells were incubated in fresh
RPMI medium with the treatments as described above.
Cytotoxic Assays
Cytotoxicity was measured using the index
of lactate dehydrogenase leakage from damaged cells and was expressed
as a percentage of total cellular activity, as described by Decker and
Lohmann-Matthes (19). Lactate dehydrogenase activity was measured using
a commercial assay kit (Cromatest, Laboratorios Knickerbocker, S.A.E.,
Barcelona, Spain).
DNA Fragmentation Analysis
For DNA fragmentation analysis,
3 × 106 L929 cells were exposed to TNF, AD, CHX,
TNF/CHX, or TNF/AD for 8-72 h. Cells were centrifuged and washed with
cold phosphate-buffered saline, and the pellet was lysed by the
addition of 400 µl of a hypotonic lysis buffer consisting of 10 mM Tris, pH 7.5, 1 mM EDTA and 0.2% Triton
X-100. Microfuge tubes were spun at 13,000 rpm for 15 min, and 350 µl
of supernatant were incubated with 106 µl of lysis buffer (150 mM NaCl, 10 mM Tris-HCl, pH 8, 40 mM EDTA, 1% SDS, and 0.2 mg/ml proteinase K, final
concentrations) for 4 h at 37 °C. DNA was extracted with
phenol/chloroform/isoamylic acid (25:25:1, v/v/v) and precipitated in
ice-cold 100% ethanol and 4 M NaCl at 20 °C for
12-18 h. After centrifugation for 5 min at 13,000 rpm and 4 °C, the
DNA pellet was washed with 500 ml of 70% ethanol and resuspended in 15 µl of 10 mM Tris, 1 mM EDTA, pH 8.5, and 50 µg/ml RNase for 1 h at 37 °C. Loading buffer (2 µl) was
added to each sample. Samples were analyzed on 1% agarose gel
containing 0.1 µg/ml ethidium bromide. The same amount of DNA, as
assessed by spectrophotometric measurement, was loaded in each lane. A mixture of HeaIII-digested X174 DNA and HindIII-digested DNA was run as a size marker.
DNA fragmentation was also measured by quantitation of apoptotic cell
death on single cell level using a flow cytometric kit (in
situ cell death detection kit, fluorescein; Boehringer Mannheim, SA, Barcelona, Spain). This test is based on the detection of single-
and double-stranded DNA breaks occurring at early stages in apoptosis.
This assay was performed according to the manufacturer's protocol.
Briefly, cells were washed twice in PBS containing 1% bovine serum
albumin and fixed in PBS containing 2% paraformaldehyde for 30 min at
room temperature. After one wash with PBS, cells were permeabilized for
2 min on ice in 0.1% Triton X-100, 0.1% sodium citrate. After two
washes with PBS, cells were resuspended in 50 µl of TUNEL mixture
(terminal deoxynucleotidyltransferase-mediated dUtp-x nick end
labeling) reaction and incubated for 60 min at 37 °C. Cells were
washed twice before they were analyzed by flow cytometry.
Flow cytometric analysis of apoptosis was also performed after DNA
staining with propidium iodide as described by Nicoletti et
al. (20). L929 cells were treated without or with TNF, TNF/AD, TNF/CHX, CHX, or AD for 8-72 h. After the treatment period, cells were
harvested, centrifuged (500 rpm for 5 min), washed once with PBS, and
resuspended in 1 ml of propidium iodide staining solution (5 µg/ml
propidium iodide in 0.1% sodium citrate, 0.1% Triton X-100). Cell
suspensions were then incubated for 30 min at 0 °C. Stained nuclei
were analyzed with an Elite Flow Cytometer (Coulter Electronics,
Hialeah, FL). Hypodiploid apoptotic cells and apoptotic bodies appear
as a sub-G0/G1 peak. The intensity of this peak is related to the amount of apoptotic cells.
Measurement of Oxygen Consumption
L929 cells were harvested
by trypsinization at the indicated times. After centrifugation for 10 min (4 °C, 500 × g), the pellet of packed cells was
resuspended in RPMI medium without serum (1 × 107
cells/ml) and placed in a polarographic chamber at 37 °C. Oxygen consumption was measured using a Clark-type electrode (Yellow Springs
Instruments Co.) fitted to a 600-µl thermally insulated sample
chamber (37 °C) under constant stirring. The oxygen consumption rate
of the whole cells was calculated by assuming that dissolved oxygen
concentration in 1 ml of media was initially 200 nmol/ml (21). The
initial rate of oxygen consumption observed after cells were added to
the chamber was termed the basal respiration. To determine the fraction
of respiration attributable to coupled oxidative phosphorylation,
oligomycin (20 µg/ml), which inhibits the
F0,F1-ATPase, was added during cellular basal
respiration. To determine the nonmitochondrial respiration, KCN (1 mM), an inhibitor of the cytochrome c oxidase,
was added during cellular basal respiration. Oxygen consumption rates
are expressed as nmol of oxygen/min/106 cells.
Lactate Assay
L-Lactic acid was determined in
the culture media using a commercial kit (Boehringer Mannheim,
Germany). Results are expressed in nmol/106 cells.
ATP/ADP Assay
Cellular, cytosolic, and mitochondrial
content of ATP and ADP were measured in trichloroacetic acid (10%,
w/v)-precipitated samples using the luciferin/luciferase reaction with
an adenosine 5 -triphosphate bioluminescent assay kit (Sigma). ADP was
converted into ATP by pyruvate kinase (22). Luminescence was measured in a bioluminometer equipped with injector (Lumat LB 9501, Berthold). Separation of cytosolic and mitochondrial compartments was carried out
by digitonin fractionation (23). After the indicated times, L929 cells
were harvested by trypsinization and suspended in ice-cold medium
containing 0.25 M sucrose, Mops buffer (pH 7.0), 3 mM EDTA, and 0.2 mg/ml digitonin. After 1 min, the
suspension was rapidly centrifuged at 3000 × g for 1 min. To determine adenine nucleotides, both pellets and supernatant
were acidified with trichloroacetic acid (10%, w/v). After removal of
proteins by centrifugation, the extracts were neutralized with 4 M KOH and frozen for later analysis. Lactate dehydrogenase
(cytosolic marker) and citrate synthase (mitochondrial marker) (24)
were measured in the supernatant to ensure a proper permeabilization
(>95% of recovery) without mitochondrial contamination. ATP:ADP
ratios were calculated from these data.
31P NMR Spectroscopy
Extracts were prepared
from 60 × 106 L929 cells or HepG2 cells. Harvested
cells were centrifuged at 4 °C and washed three times in
Hepes-buffered Hanks's balanced salt solution containing 0.1% dextrose (w/v). The cell pellet was treated with 5 volumes of cold
trichloroacetic acid 10% (w/v), followed by sonication on ice for 5 min. The extract was neutralized by 4 M KOH, the mixture was centrifuged for 30 min at 15,000 × g (4 °C),
and the supernatant was lyophilized and stored at 80 °C. For NMR
measurements, the dried homogenate was dissolved in 0.7 ml of deuterium
oxide in a 5-mm NMR tube. The pH was adjusted with deuterium chloride
to 7.4.
31P NMR spectra were recorded at 202.4 MHz on a vertical
superconducting narrow bore Bruker AMX-500 spectrometer (Kalsruhe, Germany). Spectra were collected using a 2-s repetition time and a
60° flip angle. The spectral width was 8196 Hz, and 16,000 points were collected, corresponding to about a 1-s data acquisition window.
Scans (1,000) were accumulated for each cell extract spectrum totalling
37 min. In this study, we compared the same phosphorus metabolites from
different cell lines; therefore, it was not necessary or practical to
obtain quantitative results by allowing complete relaxation.
31P chemical shifts were assigned by standardizing -ATP
to 18.7 ppm. 31P spectra were analyzed on an Aspect X32
data station. The data were zero-filled to 32,000 points,
line-broadened, and then Fourier transformed. Zero order phasing was
done, but first order phasing was unnecessary. We measured peak
intensity and peak areas with the computer. The resonance areas under
-, -, and -ATP were determined with the more commonly used
method of computer integration. The areas of the individual peaks were
determined with interactive deconvolution using standard Bruker
software (UXNMR). Initial starting values for the peaks were manually
defined and then automatically fitted with Lorentzian lines.
Measurement of Intracellular Generation of ROS
The
nonfluorescent DHR-123 probe reacts with intracellular ROS to form the
highly fluorescent rhodamine. This reaction is the basis for a
sensitive and specific assay for intracellular generation of ROS, since
DHR-123 is a stable agent that is not involved in any other biochemical
pathway, and its spontaneous oxidation to rhodamine is very low (25).
Cells were cultured in six-well plates (35-mm-diameter well). At
confluence (1 × 106 cells/plate), cells were treated
with TNF (25 ng/ml), AD (1 µg/ml), CHX (0.1 mM), or the
combined treatment TNF/AD or TNF/CHX. At the indicated times, 0.4 µl
of DHR-123 (1 µM) was added, and the incubation was
prolonged for an additional 30 min. Once the incubation was finished,
cells were harvested, washed, centrifuged (1000 rpm), resuspended in
RPMI medium, and analyzed by flow cytometry (excitation, 488 nm;
fluorescent detection, 530 nm). DHR-123 fluorescence was exclusively
analyzed on viable cells, characterized by morphology: forward scatter
versus side scatter.
Statistical Analysis
All results are expressed as
means ± S.D. unless stated otherwise. The unpaired Student's
t test was used to evaluate the significance of differences
between groups, accepting p < 0.05 as the level of
significance (26).
RESULTS
Sensitivity of L929 Cells to TNF Is Enhanced by Metabolic
Inhibitors
In this investigation, we studied the cytotoxic
activity of TNF toward L929 cells metabolically inhibited with AD or
CHX for 24 h. Fig. 1 shows that
murine L929 cells are susceptible to the cytotoxic action of TNF.
However, sensitivity of these cells to this cytokine is enhanced
significantly in the presence of CHX or AD. In the presence of 1 µg/ml AD or 0.1 mM CHX, 25 ng/ml TNF increased the cell
death from 7 ± 2% to 100% in 24 h (Fig. 1). Treatment with
either CHX or AD also yielded cytotoxic effects on L929 cells, but cell
death started later (12 ± 1 h) and was to a lesser extent
than with combined TNF treatment (Fig. 1).
Fig. 1.
Time course of the cytotoxic effect of TNF,
AD, CHX, TNF/AD, and TNF/CHX on L929 cells. L929 cells were
cultured in RPMI 1640 medium and incubated with 25 ng/ml TNF alone for
72 h ( ) or with 1 µg/ml AD ( ), 0.1 mM CHX
( ), or the combined treatment TNF/AD ( ) or TNF/CHX ( ) for
24 h. Cytotoxicity was assessed as described under "Experimental
Procedures." Values shown are means ± S.D. of three independent
experiments.
[View Larger Version of this Image (21K GIF file)]
Apoptosis was identified on the basis of the occurrence of
internucleosomal DNA cleavage on agarose gel electrophoresis. The electrophoretic pattern of the DNA extracted from TNF-treated cells
showed fragments of molecular weights corresponding to multiples of
about 180 base pairs at 48 and 72 h, but not at 24 h, of
incubation (Fig. 2A).
Similarly, laddering of DNA was induced in L929 cells treated with
actinomycin D (1 µg/ml) for 24 h. Finally, DNA fragmentation was
observed in cells exposed to TNF/AD for 8 h or more. These results
were supported by the quantitative measurement of fragmented DNA using
two different methods (TUNEL assay and
sub-G0/G1 peak). The time course study of DNA
fragmentation in L929 cells incubated with TNF/AD showed that
significant DNA cleavage (17 ± 1.3%) was first seen by the TUNEL
assay after 8 h of treatment, reaching 61.2 ± 5.8% and
100% after 12 and 24 h, respectively, of incubation (Fig.
2B). Similar results were obtained when apoptosis was
quantified by measuring the sub-G0/G1 peak
(Fig. 2C). Incubation of cells with TNF or AD alone also
elicited DNA fragmentation, but the slope of the time curve was more
attenuated than the slope of the curve caused by TNF/AD treatment. DNA
fragmentation after 12 and 24 h of incubation with AD was
13.4 ± 1.9 and 22.5 ± 1.8%, respectively. At 24, 48, and
72 h of treatment with TNF, the DNA fragmentation was 8.2 ± 1.1%, 23.1 ± 9.3% and 39.4 ± 0.7%, respectively.
Fig. 2.
Time course of DNA fragmentation.
A, DNA fragmentation evaluated by agarose gel
electrophoresis. Lanes M, mixture of HaeIII-digested X174 DNA and HindIII-digested
DNA as molecular weight marker. Lanes C, untreated
cells. Lanes T, cells treated with 25 ng/ml TNF. Lanes
A, cells treated with 1 µg/ml AD. Lanes TA, cells
treated with TNF and AD. Panel B, DNA fragmentation determined by the TUNEL assay. L929 cells were incubated with 25 ng/ml
TNF, 1 µg/ml AD, or the combination of both substances for the
indicated times. Panel C, DNA fragmentation quantified by
measuring the sub-G0/G1 peak. Cells were
treated as in panel B. The TUNEL assay and measurement of
the sub-G0/G1 peak were done by flow cytometry
as described under "Experimental Procedures." Data represent the
mean ± S.D. of three independent experiments. , TNF/AD; ,
AD; , TNF.
[View Larger Version of this Image (45K GIF file)]
TNF/AD and TNF/CHX Increase the Intracellular ATP
Content
TNF/AD and TNF/CHX induced a biphasic increase in
intracellular content of ATP during the first 6 h of treatment
(Fig. 3). After 3 h of incubation
with TNF/AD or TNF/CHX, the ATP content in cells increased by 44 and
52%, respectively (p < 0.001, for both cases), over
the basal level. At 4 h, ATP content had declined to control
levels. However, 2 h later, cellular ATP content was enhanced
again by 19 and 27%, respectively (p < 0.001, for
both cases). These early increases were followed by a progressive
decrease in cellular ATP content until 24 h, at which time
cellular ATP was almost undetectable (Fig. 3). This late decrease
coincided in time with the release of LDH, which began at 5-6 h of
incubation and was steadily enhanced until 24 h. None of these
changes were seen in untreated cells. The slight decrease in cellular
ATP levels observed in control cells after 24 h of incubation can
be ascribed to the depletion of nutrients in the culture medium.
Treatment of L929 cells with AD or CHX, but not with TNF, enhanced
intracellular ATP levels significantly for the 24 h of
observation. However, these elevations were significantly less marked
than those obtained after 2 and 3 h of treatment with TNF/AD or
TNF/CHX. While these conditions resulted in the death of about 80% of
cells at 12 h of incubation, treatment with TNF, AD, or CHX alone
did not cause any cell death at this time (Fig. 1). Treatment with TNF
alone has no effect on cellular ATP levels during the 72 h of
incubation, although about 60% of cells have died at this time, and
39% showed apoptotic features (Fig. 2).
Fig. 3.
Effect of TNF/AD and TNF/CHX on cellular ATP
content in L929 cells. L929 cells were cultured in RPMI 1640 at
37 °C in the absence (Control) ( ) or presence of 1 µg/ml AD (×), 25 ng/ml TNF ( ), and the combined treatment TNF/AD
( ) (panel A) or 0.1 mM CHX ( ) and the
combined treatment TNF/CHX ( ) (panel B). The ATP content
and cytotoxicity (····) of TNF/AD and TNF/CHX were assessed as
described under "Experimental Procedures." Values given are
means ± S.D. of eight independent experiments. ATP values were
normalized to the number of surviving cells. **, p < 0.01; ***, p < 0.001 between control and experimental
cells. a, p < 0.001 between TNF/AD and AD
or TNF/CHX and CHX.
[View Larger Version of this Image (31K GIF file)]
Effects of TNF/AD on cytosolic and mitochondrial ATP content were
similar to those found in total cellular ATP. The cytosolic ATP level
reached its maximum at 2 h, and mitochondrial ATP reached its
maximum 1 h later (Table I). At
4 h, both cytosolic and mitochondrial ATP decreased to control
level. The ADP content did not change significantly during the 4 h
of treatment with TNF/AD (Table I). Therefore, determination of the
ATP:ADP ratio, as a measurement of the energy charge, showed that at
2 h, TNF/AD increased this ratio markedly in the cytosolic
compartment. These results obtained by a luminometric method were
confirmed by 31P NMR spectroscopy of cellular extracts.
After 2 h of incubation with TNF/AD, the area of the peaks
assigned to ATP increased by 68 ± 11%. This elevation was also
significantly more marked than those induced by AD alone (AD, 43 ± 10%; TNF/AD, 68 ± 11%, p < 0.01). The
intensity of the peaks assigned to ADP did not change during treatment
with TNF/AD or AD alone (Fig. 4).
Pi peaks exhibited a significant decrease both in TNF/AD-
and AD-treated cells.
Table I.
Effects of TNF and AD on cytosolic and mitochondrial ATP and ADP and
the ratios on L929 cells
Cells were incubated with TNF (25 ng/ml) and AD (1 µg/ml) or TNF/AD
for 2, 3 and 4 h. After the indicated incubation period, the cells
were harvested and suspended in ice-cold medium containing sucrose,
Mops buffer, EDTA, and digitonin. After 1 min, the suspension was
centrifuged at 3000 × g, for 1 min. ATP and ADP
contents were measured in the mitochondrial pellet and supernatant
(cytosolic fraction) as described under "Experimental Procedures."
Values shown are means ± S.D. of six independent experiments. *,
p < 0.05; **, p < 0.01; ***,
p < 0.001 between control and experimental cells.
|
|
ATP
|
2 h
|
3 h
|
4 h
|
| Cytosolic |
Mitochondrial |
Cytosolic |
Mitochondrial |
Cytosolic |
Mitochondrial
|
|
|
nmol/106 cells
|
| Control |
7.60 ± 0.27 |
0.50
± 0.09 |
8.30 ± 1.00 |
0.44 ± 0.07 |
7.36
± 0.92 |
0.39 ± 0.05 |
| TNF |
7.72 ± 1.50 |
0.50
± 0.10 |
7.86 ± 1.50 |
0.53 ± 0.13 |
8.10
± 0.60 |
0.52 ± 0.10 |
| AD |
10.90 ± 1.80** |
0.49
± 0.09 |
10.50 ± 3.00* |
0.55 ± 0.23 |
8.93
± 1.10 |
0.66 ± 0.15 |
TNF/AD
|
13.40
± 1.70***a
|
0.64 ± 0.23
|
9.70 ± 1.80
|
0.73
± 0.27*
|
7.11 ± 1.00
|
0.42
± 0.06
|
|
ADP
|
|
|
nmol/106 cells
|
| Control |
4.78 ± 0.97 |
0.49
± 0.16 |
5.64 ± 0.93 |
0.40 ± 0.08 |
5.39
± 0.93 |
0.35 ± 0.03 |
| TNF |
5.29 ± 0.84 |
0.43
± 0.10 |
4.63 ± 0.86 |
0.50 ± 0.16 |
5.28
± 0.77 |
0.52 ± 0.01 |
| AD |
6.00 ± 0.57 |
0.44
± 0.10 |
5.80 ± 1.00 |
0.48 ± 0.06 |
6.41
± 0.59 |
0.58 ± 0.24 |
TNF/AD
|
5.41
± 0.89
|
0.50 ± 0.17
|
5.44 ± 1.12
|
0.57
± 0.13
|
6.03 ± 0.47
|
0.46
± 0.03
|
|
ATP/ADP
|
|
| Control |
1.58 ± 0.27 |
1.02 ± 0.24 |
1.47
± 0.22 |
1.11 ± 0.15 |
1.36 ± 0.13 |
1.11 ± 0.14
|
| TNF |
1.45 ± 0.34 |
1.16 ± 0.24 |
1.69
± 0.37 |
1.06 ± 0.19 |
1.53 ± 0.26 |
1.00 ± 0.01
|
| AD |
1.81 ± 0.36 |
1.11 ± 0.07 |
1.81
± 0.27 |
1.14 ± 0.44 |
1.39 ± 0.14 |
1.13 ± 0.19
|
| TNF/AD |
2.47 ± 0.50**a |
1.28 ± 0.14 |
1.77
± 0.21 |
1.28 ± 0.21 |
1.17 ± 0.16*a |
0.91
± 0.20 |
|
|
a
p < 0.05 between TNF/AD and AD.
|
|
Fig. 4.
Panel A, 31P NMR spectra
(202.46 MHz) of trichloroacetic acid extracts of control L929 cells,
and cells treated with TNF (25 ng/ml), AD (1 µg/ml), or TNF/AD for
2 h. PE, phosphorylethanolamine; PC,
phosphorylcholine; NAD + UDPG, nicotinamide adenine
dinucleotide and uridine diphosphoglycoside. Panel B,
percentage of change induced by TNF, AD, or TNF/AD treatment on ATP and
ADP levels measured by 32P NMR spectroscopy. Peak
intensities and peak areas of all deconvoluted ATP and ADP spectral
peaks were measured as indicated under "Experimental Procedures."
Data are expressed as percentage of change and represent means ± S.D. of three independent experiments. a, p < 0.01 between TNF/AD and AD.
[View Larger Version of this Image (20K GIF file)]
To determine the relevance of these findings, we tested the ability of
TNF to increase ATP levels in the human hepatoma HepG2 cell line. TNF
added to these cells did not change cellular ATP significantly and did
not induce cell death either. However, sensitivity of these cells to
this cytokine increased in the presence of AD. Treatment of HepG2 cells
with TNF/AD led to a marked increase in cell death at 24 h and to
cyclic changes in the ATP content similar to those induced in L929
cells. Cellular ATP increased after 1 and 4 h of treatment but
decreased at 3 and 6 h (Fig. 5A). Both ATP increase and
cell death were significantly higher in cells treated with TNF/AD than
in those incubated with AD alone (Fig. 5, A and
B).
Fig. 5.
Effect of TNF, AD, and TNF/AD on cellular ATP
content in HepG2 cells. Panel A, HepG2 cells were cultured
in Dulbecco's modified Eagle's medium at 37 °C for 24 h in
the absence (Control) (×) or presence of 1 µg/ml AD
( ), 25 ng/ml TNF ( ), and the combined treatment TNF/AD ( ). The
ATP content and TNF/AD cytotoxicity ( -) and AD cytotoxicity
(····) were assessed as described under "Experimental
Procedures." Values given are means ± S.D. of three independent
experiments. ATP values were normalized to the number of surviving
cells. ***, p < 0.001 between control and experimental cells. a, p < 0.01, between TNF/AD and AD.
Panel B, percentage of change induced by TNF, AD, or TNF/AD
treatment for 1 h on ATP and ADP levels measured by
31P NMR spectroscopy in HepG2 cells. Peak intensities and
peak areas of all deconvoluted ATP and ADP spectral peaks were measured
as indicated under "Experimental Procedures." Data are expressed as
percentage of change and represent means ± S.D. of three
independent experiments. a, p < 0.05 between TNF/AD and AD.
[View Larger Version of this Image (27K GIF file)]
Effects of TNF/AD and TNF/CHX Treatments on Lactate
Production
Because glycolysis contributes to the formation of
ATP, we studied the effects of these treatments on the glycolysis rate by measuring lactate concentration in the culture medium. As Fig. 6 shows, ATP accumulation in L929 cells
cannot be ascribed to an increased glycolysis, since lactate levels in
culture medium did not change significantly during the initial 2-3 h
of incubation. After 4 h, both TNF/AD and TNF/CHX caused a
significant accumulation of lactate in the medium, indicating that
glycolysis increased after this time (Fig. 6).
Fig. 6.
Effect of TNF, AD, CHX, TNF/AD, and TNF/CHX
on lactate accumulation. L929 cells were cultured in RPMI medium
without serum at 37 °C for 8 h in the absence
(Control) (×) or presence of 25 ng/ml TNF ( ), 1 µg/ml
AD ( ), 0.1 mM CHX ( ), and the combined treatments
TNF/AD ( ) and TNF/CHX ( ). Lactate was measured as described under
"Experimental Procedures." Values shown are means ± S.D. of
three independent experiments. Results are expressed as
nmol/106 cells. ***, p < 0.001; **,
p < 0.01 between control and experimental cells;
a, p < 0.01 between TNF/AD and AD or
TNF/CHX and CHX.
[View Larger Version of this Image (22K GIF file)]
Treatment of cells with either AD or CHX also resulted in an increase
in the lactate concentration after 4 h of incubation, although it
was significantly lower than the increase caused by the combined
treatment with TNF. In the absence of metabolic inhibitors, TNF
increased lactate moderately through all of the incubation period (Fig.
6).
TNF/AD and TNF/CHX Alter the Coupling between Mitochondrial
Electron Transport and Oxidative Phosphorylation
Most ATP
synthesis takes place during the mitochondrial respiration. Therefore,
we analyzed the effects of TNF, AD, CHX, and TNF/AD or TNF/CHX on the
oxygen consumption by L929 cells in RPMI medium in the presence or
absence of either oligomycin or KCN. These conditions allow us to
determine the basal respiration, the coupled respiration, and the
nonmitochondrial respiration.
Through the first 8 h of incubation, the total basal respiration
and the nonmitochondrial respiration did not change significantly by
any of these treatments. Nevertheless, there were major changes in the
oligomycin-sensitive respiration, which provides us information about
the coupling degree between the mitochondrial electron flux and the ATP
synthesis by the mitochondrial ATPase.
In basal conditions, L929 cells consumed 1.87 ± 0.20 nmol of
O2/min/106 cells (Fig.
7A). About 20 ± 2% of
the respiration rate was insensitive to cyanide, and it should be
attributed to nonmitochondrial reactions. When oligomycin was added to
the polarographic chamber, the oxygen consumption decreased by 32 ± 3%, indicating the degree of coupled respiration. The remaining
48 ± 3% represents the uncoupled respiration (Fig.
7A).
Fig. 7.
Panel A, determination of the
quantitative importance of the nonmitochondrial and
oligomycin-sensitive respiration on TNF-, AD-, TNF/AD-, and
TNF/CHX-treated L929 cells. L929 cells were treated during 2 h in
the absence (control) or presence of 25 ng/ml of TNF, 1 µg/ml AD, 0.1 mM CHX, and the combined treatments TNF/AD and TNF/CHX. The
respiration rate in RPMI medium was measured in the absence and
presence of oligomycin (20 µg/ml) to prevent oxidative
phosphorylation and in the presence of KCN (1 mM) to prevent mitochondrial respiration. Results are expressed as the percentage of total respiration (indicated above each
bar). Values shown are means ± S.D. of three
independent experiments. *, p < 0.01 between control
and experimental cells; a, p < 0.01 between TNF/AD and AD or TNF/CHX and CHX. Panel B, coupled
respiration in TNF-, AD-, CHX-, TNF/AD-, and TNF/CHX-treated L929
cells. L929 cells were cultured for 72 h in RPMI medium with 25 ng/ml TNF ( ) or for 8 h with 1 µg/ml AD ( ), 0.1 mM CHX ( ), TNF/AD ( ), or TNF/CHX ( ). Coupled
respiration was determined as the oligomycin-sensitive respiration.
Results are expressed as the percentage ± S.D. of coupled
respiration in control cells of three independent experiments. *,
p < 0.01 between control and experimental cells;
a, p < 0.01; aa,
p < 0.001 between TNF/AD and AD or TNF/CHX and
CHX.
[View Larger Version of this Image (36K GIF file)]
Treatment of cells with TNF alone increased the respiratory coupling
from 32 ± 3% of the total respiration in untreated cells to
47 ± 3% and 42 ± 2.8% in cells treated with TNF for 2 and
3 h, respectively (p < 0.01) (Fig.
7A). After this time, coupled respiration decreased and
remained at the control levels for the next 69 h (Fig.
7B). Treatment either with AD or CHX induced a smooth cyclic
change of the coupled respiration (Fig. 7B). At 2 h of
incubation, the coupled respiration was only 20 ± 1 and 19 ± 4%, respectively, of the total respiration (p < 0.01 against the control) (Fig. 7A).
Finally, the cytotoxic treatment combining TNF/AD or TNF/CHX induced
marked cyclic changes in the coupled respiration. At 2 and 3 h of
incubation, the presence of TNF increased the respiratory coupling as
compared with AD or CHX alone (Fig. 7B). At 4 h, there was a great decrease of coupling, and at 6 h, this returned to control levels. Again, there was a huge decrease in respiratory coupling after 6 h of incubation (Fig. 7B). These
cyclic changes in the coupled respiration induced by the TNF in
metabolically inhibited L929 cells were closely correlated with those
induced in the intracellular ATP levels (r = 0.98, p < 0.01 for TNF/CHX-treated cells; r = 0.93, p < 0.05 for TNF/AD-treated cells).
To elucidate the cause of the elevated respiratory coupling through the
first 3 h of incubation with TNF, we investigated whether
treatment with this cytokine enhances ATP consumption and, thus,
whether it is able to modulate the respiratory coupling in a short
period without changing significantly the total respiration rate. To
approach this issue, we prevented de novo synthesis of mitochondrial ATP by incubating L929 cells with oligomycin and measured
the effect of TNF on the cellular ATP content in the absence and
presence of AD and CHX. In all of these conditions, we measured the
lactate production to assess any change in the glycolysis rate. As Fig.
8 shows, AD increased cellular ATP
content over the control level, which suggests that the consumption of ATP was reduced by AD treatment. A similar effect was observed when
protein synthesis was inhibited by CHX. On the contrary, TNF decreased
significantly intracellular ATP content in comparison with control
cells and cells treated with AD or CHX alone. This effect of TNF on ATP
levels suggests that this cytokine increases energy consumption by a
process independent of the gene transcription or protein synthesis
(Fig. 8).
Fig. 8.
Effect of TNF on the ATP content on
oligomycin-inhibited cells. L929 cells inhibited by 10 µg/ml
oligomycin ( ) were cultured during 3 h in the presence of 1 µg/ml AD (O+AD) or 0.1 mM cycloheximide
(O+CHX), with and without 25 ng/ml of TNF. ATP content was
determined as described under "Experimental Procedures." Values
given are means ± S.D. of three independent experiments. *,
p < 0.05; **, p < 0.001.
[View Larger Version of this Image (20K GIF file)]
Blockade of Mitochondrial Respiration Prevented the Increase in
Intracellular ATP Content at 3 h and Apoptotic Cell Death Induced
by TNF/AD
Previous experiments have suggested that the increase
in intracellular ATP induced by TNF/AD or TNF/CHX was a result of the mitochondrial respiration. To assess this relationship, we studied the
effects of blockade of mitochondrial respiration on the ATP content in
L929 cells treated with TNF/AD or TNF/CHX. We added the mitochondrial
inhibitors simultaneously with TNF, since we have previously found that
the pretreatment of L929 cells with mitochondrial inhibitors resulted
in a significant decrease in the binding of human TNF to cell surface
receptors (27). As expected, incubation of these cells with any
inhibitor of cellular respiration for 3 h resulted in a
significant decrease in the intracellular ATP levels (Fig.
9). In TNF/AD-treated cells, inhibition of NADH-coenzyme Q reductase with 2 µM rotenone decreased
cellular ATP content from 14.3 ± 0.93 to 7.30 ± 1.4 nmol/106 cells (p < 0.01). TTFA, an
inhibitor of the electron transport at complex II, decreased cellular
ATP to 6.6 ± 1.3 nmol/106 cells (p < 0.01). Antimycin A (5 µg/ml), an inhibitor of the b-c1 complex, diminished ATP content in cells to
3.45 ± 0.53 nmol/106 cells (p < 0.001). Finally, blockade of ATPase with 10 µg/ml oligomycin
decreased cellular ATP to 2.90 ± 0.66 nmol/106 cells
(p < 0.001). These results indicate that accumulation
of ATP in cells exposed to TNF/AD for 3 h depends on normally
functioning mitochondrial respiration. Similar results were obtained
when mitochondrial electron transport was inhibited in cells treated with TNF/CHX (Fig. 9).
Fig. 9.
Effect of mitochondrial inhibitors on the ATP
content in TNF/AD- or TNF/CHX-treated L929 cells. L929 cells were
treated for 3 h with 25 ng/ml TNF and 1 µg/ml AD or with 25 ng/ml TNF and 0.1 mM CHX in the absence or presence of
inhibitors of mitochondrial respiration. The ATP content was determined
as described under "Experimental Procedures." Values shown are
means ± S.D. of three independent experiments. TNF/AD is 25 ng/ml
TNF plus 1 µg/ml AD; TNF/CHX is 25 ng/ml TNF plus 0.1 mM
CHX. +Rote., 2 µM rotenone; +TTFA,
250 µM TTFA; +Anti., 5 µg/ml antimycin A;
+Oligo., 10 µg/ml oligomycin; a,
p < 0.001 between control and TNF/AD- or
TNF/CHX-treated cells. *, p < 0.01; **,
p < 0.001 between the presence and absence of
mitochondrial inhibitors in TNF/AD- or TNF/CHX-treated cells.
[View Larger Version of this Image (24K GIF file)]
To investigate the implications, if any, of these changes in the
mitochondrial function on the cytotoxic effect of TNF/CHX treatment, we
measured apoptotic cell death induced by this treatment in the absence
or presence of a variety of mitochondrial blockers. Our study showed
that these agents reduced the cytotoxicity of TNF/CHX treatment. Thus,
TNF/CHX killed 94 ± 4% of cells after 24 h of incubation,
while this treatment killed only 9.5% of cells in the presence of 10 µg/ml oligomycin (Fig.
10A). Similar effects were
obtained when mitochondrial electron transport was blocked with 10 µg/ml antimycin A. In this case, apoptosis decreased from 94 ± 4 to 15%. This percentage was not much higher than the 9 ± 3%
of apoptotic cell death caused by antimycin A alone (Fig. 10B). Rotenone (2 µM), which decreased ATP
levels by about 50%, reduced cytotoxicity of TNF/CHX from 94 ± 4 to 60 ± 6% (Fig. 10C). Finally, 250 µM
TTFA reduced apoptosis to 53 ± 6% (Fig. 10D). After blocking mitochondrial electron transport, intracellular concentrations of ATP correlated significantly with the cytotoxicity of TNF/AD treatment (r = 0.89; n = 11;
p < 0.01).
Fig. 10.
Effect of mitochondrial inhibitors on the
TNF/CHX-induced DNA fragmentation. L929 cells were incubated for
24 h with 25 ng/ml TNF and 0.1 mM CHX in the absence
( ) or presence ( ) of one of the following inhibitors of the
mitochondrial respiration: 10 µg/ml oligomycin (panel A),
5 µg/ml antimycin A (panel B), 2 µM rotenone
(panel C), or 250 µM TTFA (panel
D). Apoptosis caused by mitochondrial inhibitors ( -) is shown
in each case. Apoptosis was quantified by measuring the
sub-G0/G1 peak and is expressed as the
percentage of cells with DNA fragmentation. Values shown are means ± S.D. of three independent experiments. TNF, CHX, and the inhibitor
were added to the cells simultaneously at time 0. Panel E,
flow cytometry histograms of L929 cells treated with 25 ng/ml TNF and
0.1 mM CHX for 24 h in the absence or presence of
mitochondrial inhibitors added to the cells at time 0. After the
incubation time, cells were stained with propidium iodide, and their
DNA content was analyzed by fluorescence flow cytometry. The position
of the sub-G0/G1 peak, integrated by apoptotic
hypodiploid cells, is marked by line A. The
number shown in each histogram represent the percentage of
apoptotic cells. Data shown are from a single experiment representative
of two independent experiments with similar results. Mitochondria
electron flow was inhibited as indicated in panels A,
B, C, and D.
[View Larger Version of this Image (35K GIF file)]
To make sure that increased intracellular ATP levels induced by TNF in
metabolically inhibited cells are related to its cytotoxicity, we
studied the effect of this treatment on the apoptotic cell death and
cellular ATP concentration in the absence or presence of increasing
concentrations of oligomycin. Oligomycin reduced apoptotic cell death
induced by TNF/AD treatment in a dose-related fashion (Fig.
11A). Thus, apoptosis
decreased from 74% to 34, 15, and 11% in the presence of 0.01, 1, and
10 µg/ml oligomycin, respectively. As expected, this effect was
associated with a reduced increase in the cellular ATP level in
response to TNF/AD treatment (Fig. 11B). The degree of
apoptosis induced by TNF treatment in metabolically inhibited cells
correlated significantly with the intracellular ATP content at 3 h
of incubation (r = 0.91; n = 16;
p < 0.001) (Fig. 11C).
Fig. 11.
Dose response effect of oligomycin on
TNF/AD-induced apoptotic cell death and increase in intracellular ATP
content. L929 cells were incubated with 25 ng/ml TNF and 1 µg/ml
AD in the absence or presence of increasing concentrations of
oligomycin. The ATP content was determined after 3 h of treatment
as described under "Experimental Procedures." Apoptosis was
quantified after 24 h of treatment by fluorescence flow cytometry
as described under "Experimental Procedure." Panel A,
flow cytometry histograms of untreated L929 cells (control) or cells
treated with TNF and AD (TNF/AD) alone or in the presence of 0.01-10
µg/ml oligomycin (Oligo) for 24 h. The position of
apoptotic cells is indicated by line A. The
number shown in each histogram represents the percentage of
apoptotic cells. Data shown are from a single experiment representative of two independent experiments. Panel B, effect of
oligomycin on the DNA fragmentation (····) and intracellular
ATP content (bars) induced by TNF/AD treatment. Values shown
are means ± S.D. of two independent experiments. Panel
C, correlation between intracellular ATP content at 3 h and
apoptosis at 24 h in cells treated with TNF/AD or TNF/CHX in the
presence or absence of mitochondrial inhibitors. Values of apoptosis or
ATP levels in each experimental condition were converted into
percentages of those found in cells treated with TNF/CHX.
[View Larger Version of this Image (37K GIF file)]
TNF/AD and TNF/CHX Induce Oxidative Stress
Because cytotoxic
activity of TNF toward metabolically inhibited L929 cells has been
ascribed to ROS generated in mitochondria, we investigated
intracellular production of ROS by L929 cells in response to TNF/AD and
TNF/CHX treatments using the DHR-123 probe. As Fig.
12A shows, these treatments
induced a marked increase in the ROS generation, which started after
4 h of incubation and was maintained until cell death. Blockade of
the mitochondrial respiratory chain with rotenone, antimycin A,
mixothiazol, or cyanide or blockade of the ATPase with oligomycin
prevented this increase in ROS generation. TTFA and malonate were less
effective and decreased ROS generation significantly only in cells
treated with TNF/CHX (Fig. 12B). Incubation of cells with
TNF alone enhanced ROS generation but only after 72 h of
treatment. AD and CHX treatments also increased the formation of ROS,
but these changes were less marked than those obtained when these
agents were added in combination with TNF (Fig. 12A).
Fig. 12.
Effect of TNF/AD and TNF/CHX on cellular
generation of ROS. Panel A, cells were incubated with TNF
(25 ng/ml), AD (1 µg/ml), CHX (0.1 mM), or the combined
treatment with TNF/AD or TNF/CHX for the indicated times. a,
p < 0.05; b, p < 0.01;
c, p < 0.001 between control and
metabolically inhibited cells. *, p < 0.01 between
control and TNF-treated cells. Panel B, cells were treated
for 6 h with 25 ng/ml TNF and 1 µg/ml AD or TNF and 0.1 mM CHX in the presence or absence of one of the following inhibitors: 2 µM rotenone (+Ro.), 5 µg/ml
antimycin A (+A.A.), 250 µM TTFA
(+TTFA), 1 mM cyanide (+KCN), 10 µg/ml oligomycin (Olig.), 2 µM mixothiazol
(+Mix.), or 10 mM malonate (+Mal.). Cellular generation of ROS was determined by flow cytometry using rhodamine 123 fluorescence as described under "Experimental
Procedures." Results are expressed as means of three different
experiments and represent the experimental:control ratio of the DHR-123
fluorescence. a, p < 0.001 between control
and metabolically inhibited cells (TNF/AD or TNF/CHX). In TNF/AD or
TNF/CHX-treated cells, * represents p < 0.05, **
represents p < 0.01, and *** represents
p < 0.001 between the absence and the presence of
inhibitors of the mitochondrial respiration.
[View Larger Version of this Image (36K GIF file)]
DISCUSSION
This study shows that treatment of L929 cells with a combination
of TNF and actinomycin D (TNF/AD) or cycloheximide (TNF/CHX) led to
cyclic increases in the intracellular ATP content, both cytosolic and
mitochondrial, preceding cell death (Fig. 3). ATP increases were
significantly greater than the changes induced by AD or CHX alone.
These changes in the intracellular content of ATP were also found in
the HepG2 cell line (Fig. 5) and were confirmed by 32P NMR
spectroscopy of cellular extracts (Fig. 4). This increase in
intracellular ATP content without a parallel increase in ADP levels led
to a rise in the ATP:ADP ratio, which, as has been shown, plays a
central metabolic role (28, 29).
The increase in ATP levels in cells treated with AD or CHX may be
ascribed to a decline in the ATP consumption secondary to the
inhibition of the gene transcription and protein synthesis, since these
are high energy-consuming processes (30-32). The additional and
significant increase in ATP levels induced by TNF in these metabolically inhibited cells may be a consequence of either an enhanced ATP production or a decreased ATP consumption. The rise in ATP
production may result from an increased glycolysis or from a more
active or efficient mitochondrial respiration. Our study shows that the
TNF-induced ATP increase is not a result of an enhanced rate of
glycolysis, since the accumulation of lactate did not change
significantly during the first 3 h of treatment (Fig. 6).
Similarly, treatment of cells with TNF alone or combined with CHX or AD
did not change the total rate of mitochondrial respiration (Fig.
7A). These results contrast with those obtained by others
(15), who found that these treatments inhibit mitochondrial electron
flow. The reason for this discrepancy may lie in the different
experimental conditions used in these studies. While we measured oxygen
consumption by whole cells incubated in RPMI, other authors used
digitonized cells suspended in a respiratory medium containing ADP and
a number of substrates to evaluate all complexes of the mitochondrial
respiratory chain (15).
Our study shows that although TNF alone or in combination with CHX or
AD did not induce any change in the oxygen consumption, these
treatments induced deep changes in the efficiency of mitochondrial synthesis of ATP, as assessed by measuring the degree of the
respiratory coupling. It is well known that oxidative phosphorylation
varies its coupling efficiency depending on demand without requirements for large changes in oxygen consumption rate (33). Short term changes
in the coupling between mitochondrial electron flux and oxidative
phosphorylation could be advantageous to the cells. They could adapt
the cells to short term environmental changes induced by optimizing
heat production or the rate of ATP synthesis (34).
Treatment of cells with either AD or CHX alone decreased the
respiratory coupling during the first 3 h of treatment (Fig. 7B). This change may be ascribed to the low energy
utilization induced by these agents, as was previously suggested (31).
The combined treatment of cells with either TNF/CHX or TNF/AD enhanced the respiratory coupling degree over that found in cells treated with
just CHX or AD alone (Fig. 7, A and B). This
enhanced respiratory efficacy may be responsible for the increased ATP
content we found in cells after 3 h of combined treatment. As Fig.
7B shows, this energy accumulation was followed by a large
respiratory uncoupling and by a fall in the ATP levels at 4 h.
These decreases were succeeded by a new respiratory coupling and by a
rise in the intracellular ATP levels at 6 h of incubation.
Finally, there was a significant decline in the respiratory coupling
and intracellular ATP levels, which coincided in time with the start of
cell death. ATP content and coupling degree in TNF/AD- and
TNF/CHX-treated cells were closely correlated (r = 0.93 and r = 0.98, respectively), suggesting that between
both groups of changes there may exist cause-effect relationships. The
uncoupling phase starting at 4 h of incubation may be responsible
for the marked increase in lactate production observed in cells treated
with TNF/AD and TNF/CHX (Fig. 6).
Treatment with TNF alone resulted in an increase of the respiratory
coupling during the first 3 h of treatment (Fig. 7B), without inducing any significant modification in the ATP levels (Fig.
3). These effects may be ascribed to a rise in the energy consumption
induced by TNF. Thus, the addition of TNF to L929 cells, in which ATP
synthesis had been inhibited with oligomycin, resulted in a significant
decrease in the ATP levels (Fig. 8). This increased consumption of ATP
does not appear to be related to the protein synthesis or gene
transcription, seeing that it also occurred in the presence of CHX or
AD (Fig. 8). Our study could not clarify the process in which this
enhanced ATP consumption takes place. However, we could speculate that
this rise in energy utilization might occur in any intracellular signal
transduction process induced by TNF. In these processes participate
many reactions of phosphorylation mediated by kinases (8). Thus, an
increase in respiratory coupling would compensate for the enhanced
energy consumption induced by TNF without causing any significant
change in the ATP levels.
Implications of these effects of TNF in metabolically inhibited cells
are not well understood. However, we speculate that these changes in
the cellular ATP levels might be related to the cytotoxic effect of
TNF, since inhibition of mitochondrial electron transfer prevented both
effects of TNF, the early increase in intracellular ATP content and its
cytotoxicity to L929 cells (Figs. 9 and 10). Moreover, cytotoxicity of
TNF/AD or TNF/CHX was closely correlated with ATP concentration in L929
cells inhibited with blockers of the mitochondrial respiration
(r = 0.91; n = 16; p < 0.001). The discrepancies among our results and the reports of other
authors (16, 35) can be ascribed to the different methods used to
determine cell cytotoxicity and the time at which cytotoxicity was
measured.
Our study shows that 100% of cell death caused by TNF/AD treatment for
24 h was induced by apoptosis (Figs. 2 and 10), and a
dose-response curve demonstrated that there was a close negative relationship between oligomycin-induced ATP depletion and apoptosis (Fig. 11B). Over the past few years, many investigators have
shown that the functional integrities of mitochondria and intracellular ATP are important factors during the early phases of apoptotic cell
death (36-39). Apoptosis involves the activity of hydrolytic enzymes,
chromatin condensation, and vesicle formation. Therefore, apoptosis is
considered to have a high energy demand. In accord with this concept,
Chou et al. (36) demonstrated that reduction of cellular ATP
content with antimycin A blocks AD-induced apoptotic cell death.
Likewise, Eguchi et al. (38) showed that ATP depletion induced with an inhibitor of mitochondrial ATPase completely blocks Fas/apo-1 stimulated apoptosis. Moreover, Leist et al. (39), not only confirmed that nuclear condensation and DNA fragmentation did
not occur in cells depleted of ATP but also demonstrated that ATP
replenishment was sufficient to kill cells by apoptosis.
How an early event, like TNF-induced increases in the intracellular ATP
level, might result in a late effect (apoptotic cell death) is not
known. However, there is ample evidence that apoptosis is accompanied
by oxidative stress (40-42) and that antioxidants, including Bcl-2
(41, 42), may prevent apoptosis (43, 44). The role for ROS in
TNF-mediated cell death has been postulated by many authors (15-17,
25, 45-49). The present study confirms that treatment of cells with
TNF/AD or TNF/CHX for more than 3 h was followed by a significant
increase in intracellular ROS production (Fig. 12A). In
nonphagocytic cells, mitochondria are the main source of ROS, and the
present study shows that blocking mitochondrial respiration with
rotenone, TTFA, antimycin A, or oligomycin resulted in both reduced ROS
production (Fig. 12B) and TNF-induced cell death (Figs. 10
and 11). These results are in agreement with those presented by others.
Thus, Schulze et al. (16) showed that antioxidants, iron
chelators, and some inhibitors of mitochondrial electron transport can
interfere with TNF-mediated cytotoxicity.
The present study shows that the increase in the intracellular
ATP content at 3 h was followed by a large respiratory uncoupling (Fig. 7). It is conceivable that ROS might be formed during these phases of uncoupled respiration, as it has been shown in other models
of cell death (50). Accordingly, our study demonstrated that TNF added
to metabolically inhibited L929 cells increased ROS production only
after 4 h of treatment, once respiratory coupling was more deeply
decreased (Figs. 7B and 12).
Our study has been focused on the cytotoxicity induced by TNF in the
presence of AD or CHX. However, the results obtained when TNF was added
to the cells in the absence of these metabolic inhibitors provide
evidence for a different mechanism of toxicity of this cytokine
depending on the presence or absence of these inhibitors. Thus,
treatment of L929 cells with TNF alone had no effect on cellular ATP
levels during the 72 h of incubation, although about 60% of cells
have died at this time. Furthermore, we detected an increase in ROS
generation at 72 h without any change in the degree of respiratory
coupling. All of these data suggest that the mechanism by which TNF
induces ROS generation and toxicity depends on the absence or presence
of metabolic inhibitors. This conclusion is in agreement with those of
Reid et al. (9) and Laster et al. (10), who also
suggested that the molecular mechanism of action of TNF may not be
unique but rather may depend on the cell line and the presence or
absence of metabolic inhibitors.
In conclusion, treatment of L929 cells with TNF combined with AD or CHX
induces cyclic changes in intracellular ATP content preceding cell
death, which are associated with alterations in the coupling between
mitochondrial electron flux and oxidative phosphorylation. We suggest
that these alterations might be related to the cytotoxic effect of TNF
on metabolically inhibited L929 cells by inducing changes in the
respiratory coupling and promoting the formation of ROS. However, our
study leaves open new questions. Thus, we need to know how TNF
increases the respiratory coupling in metabolically inhibited cells and
how this increase leads to a secondary respiratory uncoupling.
Moreover, new studies are needed to clarify mechanisms involved in the
TNF-induced ROS generation and its relationship with those changes in
the respiratory coupling. Finally, the mechanism of cytotoxicity of TNF
in the absence of metabolic inhibitors deserves further
investigation.
FOOTNOTES
*
This study was supported in part by "Fondo de
Investigaciones Sanitarias" Grant 95/609, by "Dirección
General de Investigación Científica y Técnica"
Grants PB94/001 and PB92/316, and by Fundación "Salud 2000,"
Spain.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence and reprint requests should be
addressed. Tel.: 34-1-390-8598; Fax: 34-1-390-8358; E-mail:
jasolis{at}h12o.es.
1
The abbreviations used are: TNF, recombinant
human tumor necrosis factor- ; AD, actinomycin D; CHX, cycloheximide;
DHR-123, dihydrorhodamine 123; Mops, 4-morpholinepropanesulfonic acid; PBS, phosphate-buffered saline; TTFA, thenoyltrifluoroacetone; TUNEL,
terminal deoxynucleotidyltransferase-mediated dUtp-X nick end labeling;
ROS, reactive oxygen species.
ACKNOWLEDGEMENT
We thank Martha E. Messman for assistance in
preparing this manuscript.
REFERENCES
-
Fiers, W.
(1991)
FEBS Lett.
285,
199-212
[CrossRef][Medline]
[Order article via Infotrieve]
-
Vilcek, J., and Lee, T. H.
(1991)
J. Biol. Chem.
266,
7313-7316
[Free Full Text]
-
Camussi, G., Albano, E., Tetta, C., and Bussolino, F.
(1991)
Eur. J. Biochem.
202,
3-14
[Medline]
[Order article via Infotrieve]
-
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B.
(1975)
Proc. Natl. Acad. Sci. U. S. A.
72,
3666-3670
[Abstract/Free Full Text]
-
Beutler, B., and Cerami, A.
(1989)
Annu. Rev. Immunol.
7,
625-655
[Medline]
[Order article via Infotrieve]
-
Grunfeld, C., and Palladino, M. A., Jr.
(1990)
Adv. Intern. Med.
35,
45-72
[Medline]
[Order article via Infotrieve]
-
Larrick, J. W., and Wright, S. C.
(1990)
FASEB J.
4,
3215-3223
[Abstract]
-
Beyaert, R., and Fiers, W.
(1994)
FEBS Lett.
340,
9-16
[CrossRef][Medline]
[Order article via Infotrieve]
-
Reid, T. R., Torti, F. M., and Ringold, G. M.
(1989)
J. Biol. Chem.
264,
4583-4589
[Abstract/Free Full Text]
-
Laster, S. M., Wood, J. G., and Gooding, L. R.
(1988)
J. Immunol.
141,
2629-2634
[Abstract]
-
Kull, F. C., and Cuatrecasas, P.
(1981)
Cancer Res.
41,
4885-4890
[Abstract/Free Full Text]
-
Ruff, M. R., and Gifford, G. E.
(1986)
in
Lymphokines (Pick, E., ed), Vol. 6, pp. 549-555, Academic Press, Inc., New York
-
Meager, A., Leung, H., and Woolley, J.
(1989)
J. Immunol. Methods
116,
1-17
[CrossRef][Medline]
[Order article via Infotrieve]
-
Matthews, N., Neale, M. L., Jackson, S. K., and Stark, J. M.
(1987)
Immunology
62,
153-155
[Medline]
[Order article via Infotrieve]
-
Lancaster, J. R., Jr., Laster, S. M., and Gooding, L. R.
(1989)
FEBS Lett.
248,
169-174
[CrossRef][Medline]
[Order article via Infotrieve]
-
Schulze-Osthoff, K., Bakker, A. C., Vanhaesebroeck, B., Beyaert, K., Jacob, W. A., and Fiers, W.
(1992)
J. Biol. Chem.
267,
5317-5323
[Abstract/Free Full Text]
-
Wong, G. H. W., Elwell, J. H., Oberley, L. W., and Goeddel, D. V.
(1989)
Cell
58,
923-931
[CrossRef][Medline]
[Order article via Infotrieve]
-
Schulze-Osthoff, K., Beyaert, R., Vandevoorde, V., Haegeman, G., and Fiers, W.
(1993)
EMBO J.
12,
3095-3104
[Medline]
[Order article via Infotrieve]
-
Decker, T., and Lohmann-Matthes, M. L.
(1988)
J. Immunol. Methods
115,
61-69
[CrossRef][Medline]
[Order article via Infotrieve]
-
Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C.
(1991)
J. Immunol. Methods
139,
271-279
[CrossRef][Medline]
[Order article via Infotrieve]
-
Oller, A. R., Buser, C. W., Tyo, M. A., and Thilly, W. G.
(1989)
J. Cell Sci.
94,
43-49
[Abstract/Free Full Text]
-
Hampp, R.
(1985)
in
Methods of Enzymatic Analysis (Bergmeyer, H. U., ed), Vol. 7, pp. 370-379, Verlag-Chemie, Weinheim, Germany
-
Zuurendonk, P. F., and Tager, J. M.
(1974)
Biochim. Biophys. Acta
333,
393-399
[CrossRef]
-
Srere, P. A.
(1969)
Methods Enzymol.
13,
3-11
[CrossRef]
-
Shoji, Y., Uedono, J., De Vos, K., and Fiers, W.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
84,
543-548
-
Colton, T.
(1979)
Estadística en Medicina, pp. 103-153, Salvat, Barcelona
-
Sánchez-Alcázar, J. A., Hernández, I., de la Torre, M. P., García, I., Santiago, E., Muñoz-Yagüe, M. T., and Solís-Herruzo, J. A.
(1995)
J. Biol. Chem.
270,
23944-23950
[Abstract/Free Full Text]
-
Atkinson, D. E.
(1968)
Biochemistry
7,
4030-4034
[CrossRef][Medline]
[Order article via Infotrieve]
-
Atkinson, D. E.
(1977)
Cellular Energy Metabolism and Its Regulation, Academic Press, Inc., New York
-
Brown, G. C.
(1992)
Biochem. J.
284,
1-13
-
Müller, M., Siems, W., Buttgereit, F., Dumdey, R., and Rapaport, S. M.
(1986)
Eur. J. Biochem.
161,
701-705
[Medline]
[Order article via Infotrieve]
-
Buttgereit, F., and Brand, M. D.
(1995)
Biochem. J.
312,
163-167
-
Brand, M. D., Chien, L.-F., Ainscow, E. K., Rolfe, D. F. S., and Porter, R. K.
(1994)
Biophys. Acta
1187,
132-139
[Medline]
[Order article via Infotrieve]
-
Murphy, M. P.
(1989)
Biochim. Biophys. Acta
977,
123-141
[Medline]
[Order article via Infotrieve]
-
O'Donnell, V. B., Spycher, S., and Azzi, A.
(1995)
Biochem. J.
310,
133-141
-
Chou, C. C., Lam, C. Y., and Young, B. Y.
(1995)
Cancer Lett.
96,
181-187
[CrossRef][Medline]
[Order article via Infotrieve]
-
Richter, C., Schweizer, M., Cossarizza, A., and Franceschi, C.
(1996)
FEBS Lett.
378,
107-110
[CrossRef][Medline]
[Order article via Infotrieve]
-
Eguchi, Y., Shimizu, S., and Tsujimoto, Y.
(1997)
Cancer Res.
57,
835-1840
-
Leist, M., Singla, B., Castoldi, A. F., Kühnle, S., and Nicotera, P.
(1997)
J. Exp. Med.
187,
1481-1486
-
Buttke, T. M., and Sandstrom, P. A.
(1994)
Immunol. Today
15,
7-10
[CrossRef][Medline]
[Order article via Infotrieve]
-
Kane, D. J., Sarafian, T. A., Anton, R., Hahn, H., Gralle, E. B., Valentine, J. S., Örd, T., and Bredsen, D. E.
(1993)
Science
262,
1274-1277
[Abstract/Free Full Text]
-
Hockenbery, D. M., Oltavi, Z., Yin, X. M., Milliman, C. L., and Korsmeyer, S. J.
(1993)
Cell
75,
241-251
[CrossRef][Medline]
[Order article via Infotrieve]
-
Steinman, H. M.
(1995)
J. Biol. Chem
270,
3487-3490
[Abstract/Free Full Text]
-
García, I., Martinou, I., Tsujimoto, Y., and Martinou, J.-C.
(1992)
Science
258,
302-304
[Abstract/Free Full Text]
-
Adamson, G. M., and Billing, R. E.
(1992)
Arch. Biochem. Biophys.
294,
223-229
[CrossRef][Medline]
[Order article via Infotrieve]
-
Stadler, J., Bentz, B. G., Harbrecht, B. G., Di Silvio, M., Curran, R. D., Billiar, T. R., Hoffman, R. A., and Simmons, R. L.
(1992)
Ann. Surg.
216,
539-546
[Medline]
[Order article via Infotrieve]
-
Hennet, T., Richter, C., and Peterhans, E.
(1993)
Biochem. J.
289,
587-592
-
Goosen, V., Grooten, J., De Vos, K., and Fiers, W.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8115-8119
[Abstract/Free Full Text]
-
Goosens, V., Grooten, J., and Fiers, W.
(1996)
J. Biol. Chem.
271,
192-196
[Abstract/Free Full Text]
-
Zamzami, N., Marchetti, P., Castedo, M., Decaudin, D., Macho, A., Hirsch, T., Susin, S. A., Petit, P. X., Mignotte, B., and Kroemer, G.
(1995)
J. Exp. Med.
187,
367-377
[Abstract/Free Full Text]
Volume 272, Number 48,
Issue of November 28, 1997
pp. 30167-30177
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Novgorodov, T. I. Gudz, and L. M. Obeid
Long-chain Ceramide Is a Potent Inhibitor of the Mitochondrial Permeability Transition Pore
J. Biol. Chem.,
September 5, 2008;
283(36):
24707 - 24717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tomiyama, S. Serizawa, K. Tachibana, K. Sakurada, H. Samejima, Y. Kuchino, and C. Kitanaka
Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors bax and bak.
J Natl Cancer Inst,
October 18, 2006;
98(20):
1462 - 1473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shimizu, T. Numata, and Y. Okada
A role of reactive oxygen species in apoptotic activation of volume-sensitive Cl- channel
PNAS,
April 27, 2004;
101(17):
6770 - 6773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Saile, N. Matthes, K. Neubauer, C. Eisenbach, H. El-Armouche, J. Dudas, and G. Ramadori
Rat liver myofibroblasts and hepatic stellate cells differ in CD95-mediated apoptosis and response to TNF-alpha
Am J Physiol Gastrointest Liver Physiol,
August 1, 2002;
283(2):
G435 - G444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-L. Guo, S. Wang, and R. W. Colman
Kininostatin, an Angiogenic Inhibitor, Inhibits Proliferation and Induces Apoptosis of Human Endothelial Cells
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2001;
21(9):
1427 - 1433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Sanchez-Alcazar, E. Schneider, M. A. Martinez, P. Carmona, I. Hernandez-Munoz, E. Siles, P. De la Torre, J. Ruiz-Cabello, I. Garcia, and J. A. Solis-Herruzo
Tumor Necrosis Factor-alpha Increases the Steady-state Reduction of Cytochrome b of the Mitochondrial Respiratory Chain in Metabolically Inhibited L929 Cells
J. Biol. Chem.,
April 28, 2000;
275(18):
13353 - 13361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Liu, V. Tergaonkar, S. Krishna, and E. J. Androphy
Human Papillomavirus Type 16 E6-enhanced Susceptibility of L929 Cells to Tumor Necrosis Factor alpha Correlates with Increased Accumulation of Reactive Oxygen Species
J. Biol. Chem.,
August 27, 1999;
274(35):
24819 - 24827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. Kristal and A. M. Brown
Apoptogenic Ganglioside GD3 Directly Induces the Mitochondrial Permeability Transition
J. Biol. Chem.,
August 13, 1999;
274(33):
23169 - 23175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. Liu, A. Z. Mohammed, W. R. Rice, D. T. Fiedeldey, J. S. Liebermann, J. A. Whitsett, T. J. Braciale, and R. I. Enelow
Perforin-Independent CD8+ T-Cell-Mediated Cytotoxicity of Alveolar Epithelial Cells Is Preferentially Mediated by Tumor Necrosis Factor-alpha . Relative Insensitivity to Fas Ligand
Am. J. Respir. Cell Mol. Biol.,
May 1, 1999;
20(5):
849 - 858.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Bai and A. I. Cederbaum
Overexpression of Catalase in the Mitochondrial or Cytosolic Compartment Increases Sensitivity of HepG2 Cells to Tumor Necrosis Factor-alpha -induced Apoptosis
J. Biol. Chem.,
June 16, 2000;
275(25):
19241 - 19249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Rogers, J. M. Monnier, and H. S. Nick
Tumor Necrosis Factor-alpha Selectively Induces MnSOD Expression via Mitochondria-to-Nucleus Signaling, whereas Interleukin-1beta Utilizes an Alternative Pathway
J. Biol. Chem.,
June 1, 2001;
276(23):
20419 - 20427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sakurai, M. Katoh, and Y. Fujimoto
Alloxan-induced Mitochondrial Permeability Transition Triggered by Calcium, Thiol Oxidation, and Matrix ATP
J. Biol. Chem.,
July 13, 2001;
276(29):
26942 - 26946.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|